A series of mouse adoptive T cell therapy studies published a decade ago showed that in vitro activated melanoma Ag (gp100)-specific TCM-like CD8 cells have a greater ability to control established melanomas in comparison with clonally-identical Teff/TEM-like cells (12, 13). The gene discussed is CD8A; the disease is melanoma.